JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jarle Vaage
Guro Valen
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tähepõld, P.
Right arrow Articles by Valen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tähepõld, P.
Right arrow Articles by Valen, G.
Related Collections
Right arrow Cardiac - physiology
Right arrow Molecular biology
Right arrow Myocardial protection

J Thorac Cardiovasc Surg 2003;125:650-660
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Hyperoxia elicits myocardial protection through a nuclear factor {kappa}B-dependent mechanism in the rat heart

Peeter Tähepõld, MD, PhDa, Jarle Vaage, MD, PhDb, Joel Starkopf, MD, PhDc, Guro Valen, MD, PhDa,b

From the Crafoord Laboratory of Experimental Surgerya and the Department of Thoracic Surgery,b Karolinska Hospital, Stockholm, Sweden, and the Institute of Biochemistry and Clinic of Anesthesiology and Intensive Care,c University of Tartu, Tartu, Estonia.

Grants were received from the Swedish Medical Research Council (11235 and 12665), The Swedish Heart-Lung Foundation, the Foundations Fredrik o Ingrid Thuring, Tore Nilsson, Åke Wiberg, The Laerdahl Foundation for Acute Medicine, Sigurd and Elsa Goljes Memory, AGA Gas, Gösta Franckel's Foundation, and the Karolinska Institutet. P.T. has been recipient of a grant from Karolinska Institutet.

Received for publication Nov 29, 2001. Revisions requested Jan 8, 2002; revisions received July 28, 2002. Accepted for publication Aug 6, 2002. Address for reprints: Guro Valen, MD, PhD, Crafoord Laboratory of Experimental Surgery, L6:00, Karolinska Hospital, S-171 76 Stockholm, Sweden (E-mail: Guro.Valen{at}cmm.ki.se).

Objective: Hyperoxia has been previously shown to protect the heart from ischemia-reperfusion injury. In the present study we investigated whether the cardioprotective effects of hyperoxia were dependent on the redox-sensitive transcription factor nuclear factor {kappa}B.
Methods: Rats were kept in a hyperoxic (>=95% O2) environment for 60 minutes. Their hearts were isolated immediately afterward, buffer perfused in a Langendorff apparatus, and subjected to 25 minutes of global ischemia and 60 minutes of reperfusion. Cardiac pressures and coronary flow were measured, and infarct size was determined by means of triphenyl tetrazolium chloride staining. Activation of nuclear factor {kappa}B was assessed by means of the electrophoretic mobility shift assay, whereas the inhibitor I{kappa}B{alpha} was evaluated by means of immunoblotting. Pharmacologic inhibition of nuclear factor {kappa}B was achieved with 2 different agents, SN50 and pyrrolidine dithiocarbamate.
Results: Preischemic exposure to hyperoxia improved postischemic recovery of myocardial contractile function and coronary flow and reduced infarct size. Hyperoxia activated pulmonary and myocardial nuclear factor {kappa}B. Pretreatment with SN50 (400 µg/kg administered intraperitoneally) or pyrrolidine dithiocarbamate (100 mg/kg administered intraperitoneally) before hyperoxia abolished the functional and infarct-limiting protection. Hyperoxia reduced nuclear factor {kappa}B activation in the heart during sustained ischemia and reperfusion and increased the cytoplasmatic inhibitory factor I{kappa}B{alpha}. Administration of pyrrolidine dithiocarbamate or SN50 during ischemia and reperfusion to isolated hearts from normoxic control animals improved postischemic contractile function and coronary flow and reduced infarct size.
Conclusions: Hyperoxia protects the rat heart against ischemia-reperfusion injury. The cardioprotection depends on myocardial activation of the transcription factor nuclear factor {kappa}B. Our results support evidence for a dual role of nuclear factor {kappa}B in the heart.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Lu, H. Liu, L. Wang, and S. Schaefer
Activation of NF-{kappa}B is a critical element in the antiapoptotic effect of anesthetic preconditioning
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1296 - H1304.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Valen
Extracardiac approaches to protecting the heart
Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 651 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Czibik, Z. Wu, G. P. Berne, M. Tarkka, J. Vaage, J. Laurikka, O. Jarvinen, and G. Valen
Human adaptation to ischemia by preconditioning or unstable angina: involvement of nuclear factor kappa B, but not hypoxia-inducible factor 1 alpha in the heart
Eur. J. Cardiothorac. Surg., November 1, 2008; 34(5): 976 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
C. Han, L. Lin, W. Zhang, L. Zhang, S. Lv, Q. Sun, H. Tao, J. H. Zhang, and X. Sun
Hyperbaric Oxygen Preconditioning Alleviates Myocardial Ischemic Injury in Rats
Exp Biol Med, November 1, 2008; 233(11): 1448 - 1453.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. R. Thom, V. M. Bhopale, D. J. Mancini, and T. N. Milovanova
Actin S-Nitrosylation Inhibits Neutrophil {beta}2 Integrin Function
J. Biol. Chem., April 18, 2008; 283(16): 10822 - 10834.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M.-L. Kaljusto, K.-O. Stenslokken, T. Mori, A. Panchenko, M.-L. Frantzen, G. Valen, and J. Vaage
Preconditioning effects of steroids and hyperoxia on cardiac ischemia-reperfusion injury and vascular reactivity
Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 355 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
B. P. Cabigas, J. Su, W. Hutchins, Y. Shi, R. B. Schaefer, R. F. Recinos, V. Nilakantan, E. Kindwall, J. A. Niezgoda, and J. E. Baker
Hyperoxic and hyperbaric-induced cardioprotection: Role of nitric oxide synthase 3
Cardiovasc Res, October 1, 2006; 72(1): 143 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
H. Choi, S.-H. Kim, Y.-S. Chun, Y.-S. Cho, J.-W. Park, and M.-S. Kim
In Vivo Hyperoxic Preconditioning Prevents Myocardial Infarction by Expressing Bcl-2
Exp Biol Med, April 1, 2006; 231(4): 463 - 472.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.